Company’s automated live cell analysis and processing system will be used.
Cyntellect is working with Burnham Institute for Medical Research to develop new applications on its in situ live cell imaging and laser processing product called LEAP™. The partners will focus on developing a method for automated purification of stem cells, stem cell colonies, and the differentiated cells derived from stem cells.
As per the agreement, Burnham will gain access to LEAP and all developments, and Cyntellect will obtain certain commercial rights to discoveries made under the collaboration.
“In situ laser processing with LEAP has provided us the unique ability to purify rare adherent cell types in an efficient, automated, and sterile manner,” points out Mark Mercola, Ph.D., professor and associate director, Del E. Webb Neuroscience, Aging and Stem Cell Research Center. “We also believe LEAP can be a transforming technology in the downstream use of stem cells and their progeny as it has clear potential as a sample-preparation system for adherent cell types derived from stem cell populations.”
LEAP is an automated cell analysis and processing system that combines optical imaging and real-time image analysis with in situ laser manipulation of cells. Using LEAP, researchers have reportedly demonstrated accelerated functional cloning of cells including highly secreting cells for biopharmaceutical manufacturing purposes, image-based cell purification of adherent and nonadherent cell types, and laser-based macromolecule delivery into cells, including siRNA, small molecules, proteins, and quantum dots.
